GB787912A - Stable steroid compositions - Google Patents

Stable steroid compositions

Info

Publication number
GB787912A
GB787912A GB10686/55A GB1068655A GB787912A GB 787912 A GB787912 A GB 787912A GB 10686/55 A GB10686/55 A GB 10686/55A GB 1068655 A GB1068655 A GB 1068655A GB 787912 A GB787912 A GB 787912A
Authority
GB
United Kingdom
Prior art keywords
sodium
vitamins
citrate
mixture
aqueous suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB10686/55A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of GB787912A publication Critical patent/GB787912A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

An aqueous therapeutic composition comprises a water-insoluble steroid subject to crystal growth in aqueous suspension, e.g. cortisone acetate, cortisone acetate hydrate, estradiol monobenzoate, testosterone propionate, progesterone or their 9 a -halo compounds, and from 0.01 to 10 per cent weight (gm.) to volume (c.c.) of polyvinyl pyrrolidone, polyvinyl alcohol or a mixture thereof. The composition may also take the form of a dry composition suitable for the extemporaneous preparation of an aqueous suspension suitable for oral, topical, or parenteral administration, and may also contain antibiotics and vitamins, e.g. penicillin O and G, procaine penicillin, bacitracin, chloramphenical, streptomycin, dihydrostreptomycin, erythromycin, oxytetracycline, chlortetracycline, tetracycline, polymyxin, circulin, endomycin, neomycin base, neomycin sulphate, hydrochloride or citrate, Vitamins A, B, B12, C, riboflavin, pyridoxine and mixture thereof. Other substances which may be present are buffers, e.g. sodium citrate, to maintain a pH of between 6.5 and 8.0, preservatives, e.g. myristyl gamma picolinium chloride, sodium ethyl mercurithiosalicylate, chlorobutanol, methylparaben, benzyl alcohol or phenol, isotonic agents, e.g. sodium chloride, lubricants, e.g. glycerol, sorbitol, wetting agents, e.g. polyoxyethylene sorbitan mono-oleate, and dextrose, sucrose, saccharin, pectin, acacia, dextran, sodium alginate, sodium citrate and benzoic acid.
GB10686/55A 1954-05-04 1955-04-13 Stable steroid compositions Expired GB787912A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US787912XA 1954-05-04 1954-05-04

Publications (1)

Publication Number Publication Date
GB787912A true GB787912A (en) 1957-12-18

Family

ID=22146248

Family Applications (1)

Application Number Title Priority Date Filing Date
GB10686/55A Expired GB787912A (en) 1954-05-04 1955-04-13 Stable steroid compositions

Country Status (1)

Country Link
GB (1) GB787912A (en)

Similar Documents

Publication Publication Date Title
US2861920A (en) Therapeutic suspensions of steroids containing pvp and/or pva
GB787912A (en) Stable steroid compositions
GB1287602A (en) 4,6-DICHLORO-Delta<4.6>-OESTRADIENES
GB739800A (en) Aqueous pharmaceutical solutions of reserpine for parenteral administration
GB1141214A (en) New derivatives of proscillaridin a
GB784201A (en) Stable solutions of relatively pure glycosides having an action on the heart
TOKUOKA Pathophysiological significance of spermine in cancer patients
GB555445A (en) Hormone preparations
AU248622B2 (en) Improvements in or relating to methods of manufacturing display screens for cathode-ray tubes
CA504683A (en) Process for the preparation of cholanic acid derivatives
GB941371A (en) Injectable pharmaceutical preparations comprising 6ª -fluoroprednisolone and/or its 21-acetate
AU453501B2 (en) 20-hydroxylated steroid derivatives and process of preparation
CA589880A (en) Process for the preparation of water-soluble derivatives of physiologically active corticord hormones
CA538738A (en) Free acid carboxyalkyl cellulose ethers and method of preparation
AU763261A (en) Improvements in or relating to methods of manufacturing display screens for cathode-ray tubes
GB999738A (en) Therapeutic compositions containing estrones
FUCHIGAMI Diagnosis of breast cancers with P32
AU1416662A (en) Method of preparing prolonged acting therapeutically active preparations for oral administration and preparations produced by said process
AU148994B2 (en) Improvements in spindles for spinning and doubling frames
AU2602871A (en) 20-hydroxylated steroid derivatives and process of preparation
AU421766B2 (en) New therapeutically active 3-or 1-oxo-dihydrobenszothiazines s-dioxides and process for their preparation
AU204017B2 (en) Preparation of 2:4-dibromo steroids
AU80351A (en) Improvements in spindles for spinning and doubling frames
AU439843B2 (en) Process for preparing derivatives of pyrrolnitrin new derivatives of pyrrolnitrin and disinfectant compositions comprising same
AU2723854A (en) Modified cellulose hydroxy acid ethers and their preparation